Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, Stepansky A, Sun G, Chobardjiev L, Riggs M, Cox H, Hakker I, Nowak DG, Laze J, Llukani E, Srivastava A, Gruschow S, Yadav SS, Robinson B, Atwal G, Trotman LC, Lepor H, Hicks J, Wigler M, Krasnitz A.

Cancer Res. 2018 Jan 15;78(2):348-358. doi: 10.1158/0008-5472.CAN-17-1138. Epub 2017 Nov 27.

PMID:
29180472
2.

Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, Tuveson DA, Trotman LC, Kinney JB, Sordella R.

Nat Commun. 2017 Feb 22;8:14370. doi: 10.1038/ncomms14370.

3.

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein.

Chen M, Nowak DG, Narula N, Robinson B, Watrud K, Ambrico A, Herzka TM, Zeeman ME, Minderer M, Zheng W, Ebbesen SH, Plafker KS, Stahlhut C, Wang VM, Wills L, Nasar A, Castillo-Martin M, Cordon-Cardo C, Wilkinson JE, Powers S, Sordella R, Altorki NK, Mittal V, Stiles BM, Plafker SM, Trotman LC.

J Cell Biol. 2017 Mar 6;216(3):641-656. doi: 10.1083/jcb.201604025. Epub 2017 Feb 13.

4.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

5.

Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.

Reyes G, Niederst M, Cohen-Katsenelson K, Stender JD, Kunkel MT, Chen M, Brognard J, Sierecki E, Gao T, Nowak DG, Trotman LC, Glass CK, Newton AC.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):E3957-65. doi: 10.1073/pnas.1404221111. Epub 2014 Sep 8.

6.

Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.

Chen M, Nowak DG, Trotman LC.

Clin Cancer Res. 2014 Jun 15;20(12):3057-63. doi: 10.1158/1078-0432.CCR-12-3680.

7.

Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors.

Labbé DP, Nowak DG, Deblois G, Lessard L, Giguère V, Trotman LC, Tremblay ML.

Mol Cancer Res. 2014 Feb;12(2):184-9. doi: 10.1158/1541-7786.MCR-13-0477. Epub 2013 Dec 30.

8.

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR.

Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016.

9.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC.

Cancer Cell. 2011 Aug 16;20(2):173-86. doi: 10.1016/j.ccr.2011.07.013.

10.

Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms.

Woolard J, Vousden W, Moss SJ, Krishnakumar A, Gammons MV, Nowak DG, Dixon N, Micklefield J, Spannhoff A, Bedford MT, Gregory MA, Martin CJ, Leadlay PF, Zhang MQ, Harper SJ, Bates DO, Wilkinson B.

Chem Sci. 2011 Feb 1;2011(2):273-278.

11.

Overexpression of VEGF165b in podocytes reduces glomerular permeability.

Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AH, Bates D, Harper SJ.

J Am Soc Nephrol. 2010 Sep;21(9):1498-509. doi: 10.1681/ASN.2009060617. Epub 2010 Aug 5.

12.

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.

Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO.

J Biol Chem. 2010 Feb 19;285(8):5532-40. doi: 10.1074/jbc.M109.074930. Epub 2009 Nov 11.

13.

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO.

J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95. doi: 10.1242/jcs.016410.

Supplemental Content

Loading ...
Support Center